GlassScriptPhysician profile
Rohan Hitendra Mandaliya
NPI 1679838510
$6,481.62
in general payments reported to CMS, 2019-2025
33 companies · $1,186 in 2025
The $1,186 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,478 · 2020: $73.58 · 2021: $249 · 2022: $508 · 2023: $1,977 · 2024: $1,011 · 2025: $1,186.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,173.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,173.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $2,618.54 | 2019-2025 | Axios, Exalt Model D, General - Metal Stents - G.I. |
| Abbvie INC. | $1,291.00 | 2019-2025 | |
| Amgen INC. | $214.15 | 2023-2025 | Uplizna, Amjevita, Avsola |
| Nestle Healthcare Nutrition INC. | $199.35 | 2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $192.93 | 2023-2025 | Xifaxan, Trulance |
| Gilead Sciences, INC. | $147.89 | 2019-2023 | |
| Genzyme Corporation | $144.09 | 2025 | |
| Pfizer INC. | $138.04 | 2019-2023 | |
| Intercept Pharmaceuticals, INC. | $128.21 | 2022-2023 | Ocaliva |
| Medtronic, INC. | $119.97 | 2022 | |
| Conmed Corporation | $113.73 | 2021 | |
| Enterra Medical, INC. | $105.36 | 2024 | |
| Aimmune Therapeutics, INC. | $103.88 | 2023-2025 | Zenpep |
| E.R. Squibb & Sons, L.L.C. | $103.68 | 2022 | |
| Digestive Care, INC. | $102.72 | 2024-2025 | Pertzye |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Qol Medical, LLC | $99.59 | 2021-2024 | Sucraid, Sucraid |
| Takeda Pharmaceuticals U.S.A., INC. | $84.33 | 2023-2025 | Entyvio, Gattex |
| Ardelyx, INC. | $75.13 | 2022-2025 | Ibsrela |
| Lumendi LLC | $73.58 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $63.29 | 2023-2025 | Dupixent |
| Incyte Corporation | $53.63 | 2023-2024 | Pemazyre |
| Eisai INC. | $42.33 | 2023 | |
| Phathom Pharmaceuticals, INC. | $40.58 | 2024-2025 | Voquezna |
| Janssen Biotech, INC. | $38.36 | 2024 | Tremfya, Stelara, Simponi |
| Alnylam Pharmaceuticals INC. | $33.25 | 2023-2024 | Givlaari |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.40 | 2023 | Cyltezo |
| Braintree Laboratories, INC. | $21.86 | 2025 | Suflave |
| Mallinckrodt Hospital Products INC. | $21.44 | 2023 | Terlivaz |
| Ferring Pharmaceuticals INC. | $20.55 | 2023 | Rebyota |
| Novo Nordisk INC | $19.34 | 2025 | Wegovy |
| Dynavax Technologies Corporation | $16.67 | 2023 | Heplisav-B |
| Ironwood Pharmaceuticals, INC | $15.28 | 2023 | Linzess |
| Endogastric Solutions, INC | $14.47 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rohan Mandaliya listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.